Trabedersen

N/A

Report date: 2024/07/01 14:21:41
NME

Base Information

Drug NameTrabedersen
Drug Alias NameOT-101OT-201AP-2/09AP-2/09-DSAP 2/09-DS +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionTransforming growth factor beta 2 inhibitors
TargetsTransforming growth factor beta 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIsarna Therapeutics Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesOncotelic Therapeutics IncAutotelicbio Co LtdUniversity of Nebraska
Inactive CompaniesIsarna Therapeutics GmbhUniversity Of Washington
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Lung NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG